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Abstract 
Rhabdomyolysis with myoglobinuria is a recognized complication of dystrophinopathies. It can be triggered by infections, exercise or 
volatile anesthetics. To our knowledge, it has never been reported in boys with Duchenne muscular dystrophy (DMD) after the administration of 
bisphosphonates. We report two patients with DMD who presented an apparent transient rhabdomyolysis with myoglobinuria after zoledronate 
administration. Possible mechanisms could involve hypophosphatemia, a known dose-dependent side effect of bisphosphonates, and/or direct 
myotoxicity of biphosphonates. Physicians and families should be aware of rhabdomyolysis with myoglobinuria as a potential uncommon 
side effect of bisphosphonates in DMD, in particular of zoledronate. 
. 
Keywords: Duchenne muscular dystrophy; myoglobinuria; bisphosphonates; zoledronate. 
1
 
g  
a  
B  
s  
b  
d  
s  
c  
p  
a  
t  
t  
a  
i  
p  
f
2
 
t  
w  
a  
B  
t  
s  
A  
a  
Published in final edited form as: Neuromuscul Disord. 2018 Oct;28(10):865-867. doi: 10.1016/j.nmd.2018.08.004.
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
2
0
0
3
8
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
. Introduction
Duchenne muscular dystrophy (DMD) is an X-linked pro-
ressive myopathy due to mutations in the dystrophin gene,
ffecting one in every 3600–10,000 live male births [1,2] .
oys with DMD typically present with delayed motor mile-
tones and muscle weakness, they progress to loss of am-
ulation around their teens, and respiratory and heart failure
uring the second decade. Corticosteroids remain the standard
upportive therapy for DMD even though new treatments re-
ently emerged [3–6] . Along with other risk factors that are
resent in DMD such as progressive weakness, immobility
nd delayed puberty, chronic corticosteroid therapy increases
he risk of low bone mineral density, exposing these patients
o fractures, pain and decreased quality of life. Little data is
vailable to guide best practice for bone health management∗ Corresponding author. Fax number: 0041 21 314 35 95 
E-mail address: anton.ivanyuk@chuv.ch (A. Ivanyuk).
s  
p  
v  
w  n DMD [7] . However, a consensus exists on the use of bis-
hosphonates to improve bone mineral density in cases of
ractures or bone pain [3,8] . 
. Case report
Patient 1 is a 14-year-old boy with DMD due to a dele-
ion of exon 50. He was diagnosed at 5 years; corticosteroids
ere initiated at 9 years old only, due to parents’ concerns
bout side-effects. Independent walking was lost at 13 years.
isphosphonates were proposed at 13 years because of in-
ractable bone pain and low bone mineral density on DEXA
can (hip Z-score –3.7 SD, lumbar spine Z-score –2.1 SD).
 first infusion of zoledronate (0.04 mg/kg) was well toler-
ted. A second infusion at the same dose was administrated
ix months later. Two days after this second infusion, the
atient developed flu-like symptoms with diffuse myalgia,
omiting, and dark brown urine. No urine or blood control
as performed during the acute phase, since the apparent
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electrolytes (notably calcium and phosphate) were normal
prior to both infusions. The 25-OH-vitamin D level was
11.9 μg/l before the first infusion and 20.8 μg/l before the
second (normal range commonly applied in paediatrics: 20–
100 μg/l). 
Patient 2 is a 13-year-old boy diagnosed at 4 years with
DMD due to a deletion of exons 12–33. Corticosteroid ther-
apy was introduced shortly after diagnosis. He lost ambulation
at 11 years. A treatment with bisphosphonates was proposed
at 13 years given the low bone mineral density on DEXA
scan (hip Z -score –5.7 SD, lumbar spine Z -score –1.2 SD)
and back pain attributed to demineralisation. An intravenous
treatment with zoledronate (0.02 mg/kg, corresponding to half
the standard dose) was initiated. Serum electrolytes (notably
calcium and phosphate) were normal prior to the treatment.
Less than 24 h after the infusion, the patient complained of
myalgia, fever, nausea, and experienced on the second day
a unique episode of dark brown urine. No urine test could
be performed during the acute phase, since the episode was
reported only after recovery. A blood test done two days
after the infusion showed hypophosphatemia (0.82 mmol/l,
range: 1.1–2.0 mmol/l) and mild hypocalcaemia (total calcium
2.01 mmol/l, range 2.15–2.55 mmol/l), which recovered after
substitution. 25-OH-vitamin D level was 13.9 μg/l (range: 20–
100 μg/l). 
3. Discussion
In the last years, as the consequences of corticosteroid-
associated osteoporosis became more and more evident, grow-
ing attention has been paid to the bone health of patients
with DMD [8,9] . Corticosteroids affect both bone resorption
and bone formation, diminish the gastrointestinal absorption
and increase the renal excretion of calcium [9] . Consequently,
corticosteroid-treated patients with DMD experience more fre-
quently bone pain due to demineralization and vertebral and
long bones fractures [9] . Additional risk factors like pro-
gressive muscle weakness, immobilization, delayed puberty,
insufficient vitamin D level and possibly inflammatory cy-
tokines increase further the risk for osteoporosis in patients
with DMD [8] . 
Bisphosphonates are the main medical treatment of pe-
diatric osteoporosis, pamidronate being the most frequently
used [10,11] . Zoledronate has been introduced more recently.
It is much more potent than pamidronate, the infusion time
is shorter and it can be administered less frequently [10] . 
Little data is available to guide the initiation, duration and
type of bisphosphonate treatment for patients with DMD [7-
9] . Current recommendations for bisphosphonate treatment in
pediatric osteoporosis are to start with a stabilization phase
during at least two years [10] . In case of persistent risk fac-
tors, a maintenance phase can be proposed, although with a
lower dose (half-dose or less), until the patient attains his
final height [10] .
Several retrospective studies and case reports have been
published on bisphosphonates for corticosteroid-treated pa-ients with DMD [12–15] . The indications to start treatment
ere variable, ranging from low bone mineral density, with
r without pain, to vertebral fractures. Most of them found an
mprovement in bone mineral density and Z-scores but effects
n pain and fracture risk were less consistent. Some patients
ontinued to have vertebral fractures while on treatment. Pro-
hylactic use of oral bisphosphonates has been described in
everal studies and showed to stabilize bone mineral density,
n effect which seemed to be greater if the treatment was
tarted earlier [13,16] . 
In our two patients, the indications for treatment initia-
ion were low bone mineral density, defined as a Z -score less
han or equal to −2.0 SD, and the presence of bone pain
17] . We decided to give zoledronate rather than pamidronate
iven its shorter infusion time and the longer interval between
wo infusions. Oral bisphosphonates were not considered as
e were concerned about the important gastrointestinal side
ffects [18] . Consequently, after zoledronate administration
oth patients developed symptoms that highly suggest tran-
ient rhabdomyolysis with myoglobinuria. A limitation of our
report is the lack of biochemical evidence for the myoglobin-
ria. However, in the reported cases, the urine was described
s dark brown (cola brown) as it has never been observed be-
ore and therefore highly indicative for myoglobinuria in this
articular context. Medical attention was not sought during
he acute phase because the next urine was less coloured and
the episodes were therefore reported only after recovery.
The prescribing information of zoledronate lists flu-like
ymptoms, myalgias and fatigue among frequent side effects,
ypocalcaemia and hypophosphataemia are also mentioned.
 risk of rhabdomyolysis is not listed, and to our knowledge
o case has been published so far, in particular not in pa-
ients with DMD [19] . A case of rhabdomyolysis following
oledronate administration in an adult was however presented
t the 2010 meeting of the Endocrine Society, and the World
ealth Organization’s (WHO) global database of reports of
uspected drug adverse effects VigiLyze® contains (as of 29
arch 2017) 47 reports of rhabdomyolysis involving zole-
ronate (Uppsala Monitoring Centre, WHO) [20,21] . 
Possible mechanisms of rhabdomyolysis secondary to bis-
hosphonates could involve drug-induced hypophosphatemia
nd/or a myotoxicity of nitrogen-containing bisphosphonates.
ypophosphatemia, as observed in our second patient, is a
nown dose-dependent side effect of bisphosphonates and a
roven risk factor for rhabdomyolysis [22,23] . Regarding my-
toxicity, an in vitro study has shown that risedronate and al-
ndronate, both nitrogen-containing bisphosphonates, induce
poptosis of rat myoblasts [24] . The inhibition of farnesyl
yrophosphate (FPP) synthase, a key enzyme of the meval-
nate pathway, is thought to underlie the observed cytotox-
city. Thus, both a direct cytotoxicity of zoledronate and an
ndirect metabolic effect (hypophosphatemia), to which a dys-
rophic muscle might be particularly sensitive, could possibly
ccount for the apparent transient rhabdomyolysis with myo-
lobinuria observed in our patients. 
Other factors could, at least partly, be involved in the ob-
erved myoglobinuria. There is a widespread practice of pre-
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Published in final edited form as: Neuromuscul Disord. 2018 Oct;28(10):865-867. doi: 10.1016/j.nmd.2018.08.004.cribing calcium supplementation for 5–10 days following the
rst bisphosphonate infusion [10] . This was not done in our
atients, the second case received supplementation but only
nce hypocalcaemia was confirmed. Further, an optimal vi-
amin D status during bisphosphonate treatment is known to
educe the risk of side effects [10] . Both our patients had low
itamin D levels. 
. Conclusion
We report two patients with DMD who presented an appar-
nt transient rhabdomyolysis with myoglobinuria after zole-
ronate administration. Possible mechanisms could involve
ypophosphatemia, a known dose-dependent side effect of
isphosphonates, and/or a possible direct myotoxicity as sug-
ested by an animal study. Phosphate supplementation is not
urrently used in patients after bisphosphonate administration.
hen considering hypophosphatemia as a possible mecha-
ism for rhabdomyolysis after bisphosphonate infusion, pre-
entive phosphate supplementation could possibly decrease
his risk. However, too little data is available to make rec-
mmendations regarding prophylactic calcium and phosphate
upplementation. Nevertheless, serum electrolytes, in partic-
lar calcium and phosphate, and vitamin D levels should be
easured and must be in the normal range prior to infusion.
Clinicians should be aware of rhabdomyolysis and myo-
lobinuria as a potential uncommon side effect of bisphospho-
ates in DMD, in particular of zoledronate, and accordingly
nform the patients and their families. 
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